National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Nivolumab in combination with ipilimumab (Opdivo® and Yervoy®) (malignant pleural mesothelioma). HTA ID: 21018

Nivolumab in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.

 

NCPE Assessment Process Complete
Rapid review commissioned 27/04/2021
Rapid review completed 13/05/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab in combination with ipilimumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.
Full pharmacoeconomic assessment commissioned by the HSE 31/05/2021
Pre-submission consultation with Applicant 20/07/2021
Full submission received from Applicant 21/01/2022
Preliminary review sent to Applicant 03/05/2022
NCPE assessment re-commenced 01/06/2022
Factual accuracy check sent to Applicant 29/07/2022
NCPE assessment re-commenced 10/08/2022
NCPE assessment completed 07/09/2022
NCPE assessment outcome The NCPE recommends that nivolumab plus ipilimumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.